Low-Concentration α-2 Agonist Compositions for Rebound-Free Vasoconstriction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing vasoconstrictor formulations cause rebound hyperemia and other side effects due to high α-1 agonist activity, leading to undesirable clinical sequelae like medicamentosa and prolonged inflammatory states, with no effective means to induce safe and long-term vasoconstriction without ischemia.

Innovation Solution

Utilizing highly selective α-2 adrenergic receptor agonists at low concentrations (below 0.05% weight by volume) to minimize rebound hyperemia and achieve effective vasoconstriction with reduced side effects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Force

If high concentration alpha adrenergic receptor agonists are used to induce vasoconstriction, then vasoconstriction effect is improved, but rebound hyperemia and side effects increase

Engineering Contradiction:

Improvevasoconstriction effectVSAvoidrebound hyperemia

Core Design Contradiction:

ForceVSObject-generated harmful factors

Solution Approach 1:

The patent changes the concentration parameter of the agonist from high (0.1-0.2% brimonidine) to low (below 0.05%), which fundamentally alters the receptor activation profile. At low concentrations, only high-affinity alpha-2 receptors are activated, avoiding alpha-1 receptor activation that leads to rebound hyperemia, while still achieving sufficient vasoconstriction effect

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent achieves selective activation of specific receptor subtypes (alpha-2 vs alpha-1) through concentration-dependent pharmacology. The low concentration formulation creates a qualitative difference in receptor binding, activating only the desired alpha-2 receptors in the target tissue while avoiding off-target alpha-1 receptor activation that causes harmful rebound effects

Inventive Principle:

Principle #3Local quality

2Force

If high concentration alpha adrenergic receptor agonists are used to induce vasoconstriction, then vasoconstriction effect is improved, but ischemia and inflammatory sequelae increase

Engineering Contradiction:

Improvevasoconstriction effectVSAvoidischemia

Core Design Contradiction:

ForceVSObject-affected harmful factors

Solution Approach 1:

The patent changes the concentration parameter to achieve a therapeutic window where vasoconstriction is sufficient for clinical benefit but remains below the threshold that causes excessive blood flow reduction leading to ischemia. The low concentration (below 0.05%) formulation provides a safety margin against ischemic complications

Inventive Principle:

Principle #35Parameter changes

3Duration of action of stationary object

If long term vasoconstriction is achieved with conventional formulations, then duration of action is improved, but rebound hyperemia and medicamentosa increase

Engineering Contradiction:

Improveduration of vasoconstrictionVSAvoidmedicamentosa

Core Design Contradiction:

Duration of action of stationary objectVSObject-generated harmful factors

Solution Approach 1:

The patent applies preliminary action by using low concentration alpha-2 selective agonists to establish sustained vasoconstriction before rebound effects can occur. The formulation is designed to maintain therapeutic effect over extended periods through consistent alpha-2 receptor activation without triggering the compensatory mechanisms that lead to rebound hyperemia and medicamentosa

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent changes the concentration parameter to a low level (below 0.05%) that enables long-term use. This low concentration activates only high-affinity alpha-2 receptors, creating a sustainable therapeutic effect that does not trigger the harmful feedback loops leading to rebound hyperemia and medicamentosa that occur with higher concentration formulations

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method provides safe and long-term vasoconstriction with significantly reduced hyperemia and allergic reactions, minimizing ischemia and inflammatory sequelae.

Implementation Method 1

Utilizing highly selective α-2 adrenergic receptor agonists at low concentrations (below 0.05% weight by volume) to minimize reboundhyperemia and achieve effective vasoconstriction with reduced side effects

Methodology Applied

Scientific EffectAdrenergic receptor agonist binding:

Data Source

PatentUS12514857B2Vasoconstriction compositions and methods of use

Publication Date: 2026.01.06 EYE THERAPIES LLC

AI summary

The invention generally relates to compositions for inducing vasoconstriction. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH from about 4.0 to about 7.5.